IncellDx HPV OncoTect 3Dx system combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay, according to the firm.
The deal covers IncellDx's portfolio of immune-oncology and oncology diagnostic products including its single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
The two companies intend to develop and commercialize several cancer and NIPT assays using a combination of their technologies.
The deal covers IncellDx's single-cell immune-oncology and oncology diagnostic products including its single-cell PD-L1 assay.
The companies will study the combination of their respective technologies for predicting patient responses to metastatic lung cancer immunotherapy.
The kit uses a proprietary non-enzymatic method to prepare intact, single-cell suspensions from tissue in less than 10 minutes.
Single-cell RNA sequencing on thousands of tumor and surrounding cells from 19 melanoma samples revealed subsets of cells with apparent resistance potential.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.